Tag: rna targeting small molecules therapeutics market scope

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

RNA Targeting Small Molecules Therapeutics Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?

The rna targeting small molecules therapeutics market size has experienced significant expansion in recent years. This market is anticipated to expand from $2.93 billion in 2025 to $3.1 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.8%. The historical growth can be attributed to factors such as the limited efficacy of protein-targeted drugs, an increase in genomic research funding, the rising prevalence of cancer and genetic disorders, the early success of rna-based therapies, and the broadening of academic-industry collaborations.

The market for RNA-targeting small molecule therapeutics is projected to experience swift expansion over the coming years. This market is anticipated to reach a valuation of $4.84 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 11.7%. Key drivers for this expansion during the projection period include breakthroughs in RNA structure prediction, a rising need for personalized treatments, heightened biotechnology investments in small molecules, favorable regulatory frameworks for innovative RNA drugs, and an expanding array of RNA-targeting clinical trials. Significant trends observed throughout the forecast timeframe encompass the broadening of RNA-targeted drug pipelines, an intensified focus on disease targets previously considered undruggable, enhanced partnerships between pharmaceutical and biotechnology companies, progress in RNA structural biology and chemistry, and increased funding for therapies addressing rare and genetic diseases.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=12253&type=smp&name=RNA%20Targeting%20Small%20Molecules%20Therapeutics%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

RNA Targeting Small Molecules Therapeutics Market Growth Factors: What’s Supporting Expansion?

The RNA-targeting small molecule therapeutics market is anticipated to expand due to the growing incidence of cancer cases. Cancer, a group of illnesses, develops when abnormal cells uncontrollably multiply in almost any organ or tissue, surpassing their usual boundaries and potentially spreading to other organs or invading nearby body parts. RNA-targeting small molecules are developed and studied to specifically target RNA molecules linked to cancer as a treatment approach. For instance, the World Health Organization, a Switzerland-based intergovernmental organization, stated in February 2024 that by 2050, more than 35 million new cancer cases are projected, indicating a 77% rise compared to the approximately 20 million cases in 2022. Consequently, the increasing number of cancer cases is a significant factor propelling the growth of the RNA-targeting small molecule therapeutics market.

RNA Targeting Small Molecules Therapeutics Market Segment Landscape And Growth Outlook

The rna targeting small molecules therapeutics market covered in this report is segmented –

1) By Offering: mRNA (Messenger Ribonucleic Acid) Translation Modulators, RNA (Ribonucleic Acid) Splicing Modification, Direct RNA (Ribonucleic Acid) Targeting, Other Offerings

2) By Therapeutic Indication: Lung Fibrosis, Cancer, Neurodegenerative Diseases, Autoimmune, Inflammatory, Other Therapeutic Indications

3) By End User: Hospitals, Research Laboratories, Pharmaceutical And Biotechnology Companies, Other End-Users

RNA Targeting Small Molecules Therapeutics Market Industry Trends: What’s Reshaping Demand?

Major companies within the RNA-targeting small molecule therapeutics market are increasingly concentrating on strategic alliances to advance the discovery and development of innovative therapies. These strategic alliances typically involve cooperative efforts between several organizations to pool expertise, exchange crucial data, and accelerate the creation of novel RNA-targeting small molecules. For example, in June 2022, Otsuka Pharmaceutical Co. Ltd., a pharmaceutical manufacturing company based in Japan, partnered with xFOREST Therapeutics Co. Ltd., a Japan-based developer of drug discovery platforms. Through this collaboration, xFOREST is poised to provide Otsuka with its Forest technology to propel systemic small-molecule drug discovery research, specifically targeting RNA structures. Additionally, in April 2024, Ipsen, a biopharmaceutical company from France, joined forces with Skyhawk Therapeutics, a US-based clinical-stage biotechnology company that specializes in RNA-targeting small molecule therapeutics. This partnership allowed Ipsen to focus on developing RNA-targeting small molecule drugs for rare neurological diseases and to integrate diverse data sets to identify and develop small molecules capable of modulating RNA.

RNA Targeting Small Molecules Therapeutics Market Competitive Landscape: Who Leads The Industry?

Major companies operating in the rna targeting small molecules therapeutics market are F Hoffmann La Roche Ltd, Novartis AG, Sanofi SA, AstraZeneca plc, Eli Lilly and Company, Amgen Inc, Bayer AG, Vertex Pharmaceuticals Inc, PTC Therapeutics Inc, Arrakis Therapeutics, Anima Biotech Inc, Skyhawk Therapeutics Inc, Remix Therapeutics, Accent Therapeutics Inc, STORM Therapeutics Ltd, eFFECTOR Therapeutics Inc, EPICS Therapeutics, Expansion Therapeutics Inc, Ribometrix Inc, Redona Therapeutics, Eloxx Pharmaceuticals Inc, 858 Therapeutics

View The Full RNA Targeting Small Molecules Therapeutics Market Report:

https://thebusinessresearchcompany.com/report/RNA-targeting-small-molecules-therapeutics-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

RNA Targeting Small Molecules Therapeutics Market Regional Analysis And Leading Geography

North America was the largest region in the RNA targeting small molecules therapeutics market in 2025. The regions covered in the rna targeting small molecules therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

RNA Targeting Small Molecules Therapeutics Market Forecast Highlighting Growth From $3.1 Billion To $4.83 Billion

The market for RNA targeting small molecules therapeutics has seen robust expansion in recent years. Projections indicate it will rise from $2.93 billion in 2025 to $3.1 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.8%. This historical growth is largely driven by the limited effectiveness of drugs aimed at proteins, increased funding for genomic research, a rising incidence of cancer and genetic disorders, early achievements in RNA-based treatments, and the broadening of partnerships between academia and industry.

The market for RNA-targeting small molecule therapeutics is projected to experience rapid expansion over the coming years. By 2030, its value is anticipated to reach $4.84 billion, reflecting a compound annual growth rate (CAGR) of 11.7%. This forecasted growth is driven by several factors, including improvements in RNA structure prediction, a heightened demand for precision-based treatments, increased biotech investments focused on small molecules, regulatory backing for innovative RNA drugs, and an expanding pipeline of clinical trials targeting RNA. Key trends shaping this period involve the broadening of RNA-targeted drug development efforts, a stronger emphasis on addressing previously undruggable diseases, more frequent partnerships between pharmaceutical and biotechnology companies, progress in RNA structural biology and chemistry, and growing financial support for therapies aimed at rare and genetic conditions.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12253&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

RNA Targeting Small Molecules Therapeutics Market Growth Momentum: Which Factors Are Influencing Demand?

The anticipated rise in cancer cases is set to drive the expansion of the RNA-targeting small molecule therapeutics market in the coming period. Cancer encompasses a range of diseases that can emerge in virtually any organ or tissue when abnormal cells grow uncontrollably, breach their normal boundaries, and invade adjacent body parts or spread to other organs. RNA-targeting small molecules are developed and studied to specifically target RNA molecules linked to cancer, offering a treatment approach. As an example, in February 2024, the World Health Organization, an intergovernmental body based in Switzerland, projected that by 2050, over 35 million new cancer cases will occur, marking a 77% rise from the estimated 20 million cases in 2022. Consequently, the growing prevalence of cancer is fueling the growth of the RNA-targeting small molecule therapeutics market.

The increasing prevalence of genetic disorders is anticipated to accelerate the growth of the RNA-targeting small molecule therapeutics market moving forward. Genetic disorders arise from abnormalities or mutations in an individual’s genetic material, including DNA or chromosomes. RNA-targeting small molecule therapeutics represent a promising and emerging field with significant potential for addressing genetic disorders. Certain genetic disorders involve toxic expansions of repeated RNA sequences, and small molecules can stabilize or destabilize these expansions, potentially reducing their detrimental effects. For instance, in October 2024, the Cystic Fibrosis Trust, a UK-based national charity, reported that 11,148 people were living with cystic fibrosis (CF) in the UK in 2022, a figure that rose to 11,318 in 2023. Thus, the growing incidence of genetic disorders is propelling the expansion of the RNA-targeting small molecule therapeutics market.

RNA Targeting Small Molecules Therapeutics Market Segment Performance And Strategic Opportunities

The rna targeting small molecules therapeutics market covered in this report is segmented –

1) By Offering: mRNA (Messenger Ribonucleic Acid) Translation Modulators, RNA (Ribonucleic Acid) Splicing Modification, Direct RNA (Ribonucleic Acid) Targeting, Other Offerings

2) By Therapeutic Indication: Lung Fibrosis, Cancer, Neurodegenerative Diseases, Autoimmune, Inflammatory, Other Therapeutic Indications

3) By End User: Hospitals, Research Laboratories, Pharmaceutical And Biotechnology Companies, Other End-Users

RNA Targeting Small Molecules Therapeutics Market Trends Reshaping Industry Growth

Key players in the RNA-targeting small molecule therapeutics market are actively pursuing strategic partnerships to boost the development and discovery of innovative treatments. Such collaborations typically bring together two or more organizations, allowing them to pool their knowledge, exchange information, and speed up the creation of new RNA-targeting small molecules. As an example, in June 2022, Otsuka Pharmaceutical Co. Ltd., a Japanese pharmaceutical firm, joined forces with xFOREST Therapeutics Co. Ltd., a Japanese developer of drug discovery platforms. Under this arrangement, xFORESS made its Forest technology available to Otsuka to facilitate systemic small-molecule drug discovery research that targets RNA structures. Additionally, in April 2024, Ipsen, a biopharmaceutical company based in France, established a partnership with Skyhawk Therapeutics, a clinical-stage U.S. biotechnology company specializing in RNA-targeting small molecule therapeutics. Through this alliance, Ipsen aimed to create RNA-targeting small molecule drugs for rare neurological conditions, integrating diverse datasets to pinpoint and develop small molecules capable of modulating RNA.

RNA Targeting Small Molecules Therapeutics Market Key Players: Which Companies Shape Industry Competition?

Major companies operating in the rna targeting small molecules therapeutics market are F Hoffmann La Roche Ltd, Novartis AG, Sanofi SA, AstraZeneca plc, Eli Lilly and Company, Amgen Inc, Bayer AG, Vertex Pharmaceuticals Inc, PTC Therapeutics Inc, Arrakis Therapeutics, Anima Biotech Inc, Skyhawk Therapeutics Inc, Remix Therapeutics, Accent Therapeutics Inc, STORM Therapeutics Ltd, eFFECTOR Therapeutics Inc, EPICS Therapeutics, Expansion Therapeutics Inc, Ribometrix Inc, Redona Therapeutics, Eloxx Pharmaceuticals Inc, 858 Therapeutics

Access The Complete RNA Targeting Small Molecules Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

RNA Targeting Small Molecules Therapeutics Market Regional Distribution: Which Areas Drive Market Expansion?

North America was the largest region in the RNA targeting small molecules therapeutics market in 2025. The regions covered in the rna targeting small molecules therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Expected Market Size Of The RNA Targeting Small Molecules Therapeutics Market In 2026 And How Much Will It Reach By 2030?

The rna targeting small molecules therapeutics market has experienced significant growth recently. It is projected to expand from $2.93 billion in 2025 to $3.1 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.8%. The market’s past growth can be attributed to various factors such as the limited efficacy of protein-targeted drugs, an increase in genomic research funding, the rising prevalence of cancer and genetic disorders, the early success of rna-based therapies, and the broadening of academic-industry collaborations.

The rna targeting small molecules therapeutics market size is projected to experience swift expansion over the coming years. This market is anticipated to reach $4.84 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.7%. Several factors are contributing to this expansion during the forecast period, including advancements in rna structure prediction, a heightened demand for precision therapeutics, increased biotechnology investments in small molecules, regulatory backing for innovative rna drugs, and an expanding pipeline of rna-targeting clinical trials. Key trends expected within this period encompass the broadening of rna-targeted drug pipelines, an escalating emphasis on previously untreatable disease targets, enhanced cooperation between pharmaceutical and biotechnology companies, progress in rna structural biology and chemistry, and a surge in investment dedicated to therapies for rare and genetic diseases.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12253&type=smp

What Are The Main Drivers Accelerating The Growth Of The RNA Targeting Small Molecules Therapeutics Market?

The expanding occurrence of cancer cases is anticipated to fuel the future expansion of the RNA-targeting small molecule therapeutics market. Cancer refers to a group of diseases characterized by abnormal cells multiplying without control, extending beyond their normal limits, and potentially spreading to other organs or invading nearby tissues. Treatment for cancer involves RNA-targeting small molecules specifically designed and researched to target RNA molecules linked with the disease. For example, the World Health Organization, an intergovernmental organization based in Switzerland, reported in February 2024 that more than 35 million new cancer cases are forecast by 2050. This represents a 77% surge from the approximately 20 million cases estimated in 2022. Consequently, the rising volume of cancer cases is a significant factor propelling the growth of the RNA-targeting small molecule therapeutics market.

Which Segment-Based Categories Are Covered In The RNA Targeting Small Molecules Therapeutics Market?

The rna targeting small molecules therapeutics market covered in this report is segmented –

1) By Offering: mRNA (Messenger Ribonucleic Acid) Translation Modulators, RNA (Ribonucleic Acid) Splicing Modification, Direct RNA (Ribonucleic Acid) Targeting, Other Offerings

2) By Therapeutic Indication: Lung Fibrosis, Cancer, Neurodegenerative Diseases, Autoimmune, Inflammatory, Other Therapeutic Indications

3) By End User: Hospitals, Research Laboratories, Pharmaceutical And Biotechnology Companies, Other End-Users

Which Trends Are Contributing To Changes In The RNA Targeting Small Molecules Therapeutics Market?

Leading companies within the RNA-targeting small molecule therapeutics market are prioritizing strategic collaborations to advance the identification and creation of novel treatments. These strategic alliances entail cooperation between multiple entities, aiming to merge specialized knowledge, exchange information, and accelerate the generation of groundbreaking RNA-targeting small molecules. For instance, in June 2022, Otsuka Pharmaceutical Co. Ltd., a pharmaceutical manufacturer based in Japan, teamed up with xFOREST Therapeutics Co. Ltd., a Japan-based firm specializing in drug discovery platform development. This partnership enables xFOREST to provide Otsuka with its Forest technology to propel systemic small-molecule drug discovery research concentrated on RNA structures. Furthermore, in April 2024, Ipsen, a biopharmaceutical company from France, joined forces with Skyhawk Therapeutics, a US-based clinical-stage biotechnology company that delivers RNA-targeting small molecule therapeutics. Through this collaboration, Ipsen aimed to develop RNA-targeting small molecule drugs for uncommon neurological conditions and incorporate diverse data sets to pinpoint and create small molecules capable of modulating RNA.

Which Industry Players Are Present In The RNA Targeting Small Molecules Therapeutics Market?

Major companies operating in the rna targeting small molecules therapeutics market are F Hoffmann La Roche Ltd, Novartis AG, Sanofi SA, AstraZeneca plc, Eli Lilly and Company, Amgen Inc, Bayer AG, Vertex Pharmaceuticals Inc, PTC Therapeutics Inc, Arrakis Therapeutics, Anima Biotech Inc, Skyhawk Therapeutics Inc, Remix Therapeutics, Accent Therapeutics Inc, STORM Therapeutics Ltd, eFFECTOR Therapeutics Inc, EPICS Therapeutics, Expansion Therapeutics Inc, Ribometrix Inc, Redona Therapeutics, Eloxx Pharmaceuticals Inc, 858 Therapeutics

Access The Complete RNA Targeting Small Molecules Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

Which Geographic Region Represents The Largest RNA Targeting Small Molecules Therapeutics Market Share?

North America was the largest region in the RNA targeting small molecules therapeutics market in 2025. The regions covered in the rna targeting small molecules therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access RNA Targeting Small Molecules Therapeutics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=12253&type=smp

Browse Through More Reports Similar to the Global RNA Targeting Small Molecules Therapeutics Market 2026, By The Business Research Company

Rna Targeting Small Molecules Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

Rna Targeting Small Molecule Drug Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecule-drug-discovery-global-market-report

Mrna Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/mrna-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Changes In Market Value Are Expected For The RNA Targeting Small Molecules Therapeutics Market Over The 2026–2030 Period?

The market size for rna targeting small molecules therapeutics has demonstrated robust growth in recent years. It is anticipated to increase from $2.93 billion in 2025 to $3.1 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.8%. This historical growth can be linked to several factors, including the constrained effectiveness of protein-targeted drugs, an uptick in genomic research funding, the rising occurrence of cancer and genetic disorders, the initial achievements of rna-based therapies, and the broadening scope of academic-industry collaborations.

The rna targeting small molecules therapeutics market size is anticipated to undergo significant expansion over the next few years. It is projected to reach $4.84 billion by 2030, progressing at a compound annual growth rate (CAGR) of 11.7%. This expansion during the forecast period is primarily driven by advancements in rna structure prediction, a growing need for precision therapeutics, increased investments by biotechnology firms in small molecules, supportive regulatory environments for new rna drugs, and a burgeoning pipeline of rna-targeting clinical trials. Dominant trends anticipated for this period involve the broadening of rna-targeted drug pipelines, an escalating emphasis on previously undruggable disease targets, enhanced collaboration between pharmaceutical and biotechnology companies, breakthroughs in rna structural biology and chemistry, and rising financial commitments towards therapies for rare and genetic conditions.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12253&type=smp

What Major Factors Are Driving The RNA Targeting Small Molecules Therapeutics Market Forward?

The projected rise in cancer diagnoses is anticipated to fuel the expansion of the RNA-targeting small molecule therapeutics market in the coming years. Cancer refers to a group of diseases that emerge when abnormal cells multiply without control, extending beyond their normal limits to invade adjacent tissues or spread to other organs throughout the body. RNA-targeting small molecules are specifically developed and studied to precisely target RNA molecules linked to cancer, offering a treatment approach for the disease. A notable example is the projection made in February 2024 by the World Health Organization, a Switzerland-based intergovernmental body, which estimates more than 35 million new cancer cases globally by 2050. This marks a significant 77% surge from the approximately 20 million cases recorded in 2022. Consequently, the growing prevalence of cancer cases is a key factor propelling the development of the RNA-targeting small molecule therapeutics market.

What Are The Main Segments Within The RNA Targeting Small Molecules Therapeutics Market Segment Structure?

The rna targeting small molecules therapeutics market covered in this report is segmented –

1) By Offering: mRNA (Messenger Ribonucleic Acid) Translation Modulators, RNA (Ribonucleic Acid) Splicing Modification, Direct RNA (Ribonucleic Acid) Targeting, Other Offerings

2) By Therapeutic Indication: Lung Fibrosis, Cancer, Neurodegenerative Diseases, Autoimmune, Inflammatory, Other Therapeutic Indications

3) By End User: Hospitals, Research Laboratories, Pharmaceutical And Biotechnology Companies, Other End-Users

What Trends Are Influencing The RNA Targeting Small Molecules Therapeutics Market?

Leading companies active in the RNA-targeting small molecule therapeutics market are prioritizing the formation of strategic alliances to improve the discovery and development of novel treatments. These strategic partnerships involve joint efforts between two or more organizations to integrate expertise, share data, and accelerate the creation of innovative RNA-targeting small molecules. For instance, in June 2022, Otsuka Pharmaceutical Co. Ltd., a Japan-based pharmaceutical manufacturing firm, teamed up with xFOREST Therapeutics Co. Ltd., a Japan-based developer of drug discovery platforms. Through this collaboration, xFOREST will provide Otsuka with its Forest technology to advance systemic small-molecule drug discovery research centered on RNA structures. Moreover, in April 2024, Ipsen, a France-based biopharmaceutical company, partnered with Skyhawk Therapeutics, a US-based clinical-stage biotechnology company that offers RNA-targeting small molecule therapeutics. With this alliance, Ipsen sought to develop RNA-targeting small molecule drugs for rare neurological diseases and integrates various data sets to identify and create small molecules capable of modulating RNA.

Who Are The Companies Participating In The RNA Targeting Small Molecules Therapeutics Market?

Major companies operating in the rna targeting small molecules therapeutics market are F Hoffmann La Roche Ltd, Novartis AG, Sanofi SA, AstraZeneca plc, Eli Lilly and Company, Amgen Inc, Bayer AG, Vertex Pharmaceuticals Inc, PTC Therapeutics Inc, Arrakis Therapeutics, Anima Biotech Inc, Skyhawk Therapeutics Inc, Remix Therapeutics, Accent Therapeutics Inc, STORM Therapeutics Ltd, eFFECTOR Therapeutics Inc, EPICS Therapeutics, Expansion Therapeutics Inc, Ribometrix Inc, Redona Therapeutics, Eloxx Pharmaceuticals Inc, 858 Therapeutics

Get The Full RNA Targeting Small Molecules Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

Which Region Represents The Largest Share Of The RNA Targeting Small Molecules Therapeutics Market?

North America was the largest region in the RNA targeting small molecules therapeutics market in 2025. The regions covered in the rna targeting small molecules therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized RNA Targeting Small Molecules Therapeutics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

Browse Through More Reports Similar to the Global RNA Targeting Small Molecules Therapeutics Market 2026, By The Business Research Company

Rna Targeting Small Molecules Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

Rna Targeting Small Molecule Drug Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecule-drug-discovery-global-market-report

Mrna Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/mrna-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Changes In Market Value Are Expected For The RNA Targeting Small Molecules Therapeutics Market Over The 2026–2030 Period?

The market size for rna targeting small molecules therapeutics has demonstrated robust growth in recent years. It is anticipated to increase from $2.93 billion in 2025 to $3.1 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.8%. This historical growth can be linked to several factors, including the constrained effectiveness of protein-targeted drugs, an uptick in genomic research funding, the rising occurrence of cancer and genetic disorders, the initial achievements of rna-based therapies, and the broadening scope of academic-industry collaborations.

The rna targeting small molecules therapeutics market size is anticipated to undergo significant expansion over the next few years. It is projected to reach $4.84 billion by 2030, progressing at a compound annual growth rate (CAGR) of 11.7%. This expansion during the forecast period is primarily driven by advancements in rna structure prediction, a growing need for precision therapeutics, increased investments by biotechnology firms in small molecules, supportive regulatory environments for new rna drugs, and a burgeoning pipeline of rna-targeting clinical trials. Dominant trends anticipated for this period involve the broadening of rna-targeted drug pipelines, an escalating emphasis on previously undruggable disease targets, enhanced collaboration between pharmaceutical and biotechnology companies, breakthroughs in rna structural biology and chemistry, and rising financial commitments towards therapies for rare and genetic conditions.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12253&type=smp

What Major Factors Are Driving The RNA Targeting Small Molecules Therapeutics Market Forward?

The projected rise in cancer diagnoses is anticipated to fuel the expansion of the RNA-targeting small molecule therapeutics market in the coming years. Cancer refers to a group of diseases that emerge when abnormal cells multiply without control, extending beyond their normal limits to invade adjacent tissues or spread to other organs throughout the body. RNA-targeting small molecules are specifically developed and studied to precisely target RNA molecules linked to cancer, offering a treatment approach for the disease. A notable example is the projection made in February 2024 by the World Health Organization, a Switzerland-based intergovernmental body, which estimates more than 35 million new cancer cases globally by 2050. This marks a significant 77% surge from the approximately 20 million cases recorded in 2022. Consequently, the growing prevalence of cancer cases is a key factor propelling the development of the RNA-targeting small molecule therapeutics market.

What Are The Main Segments Within The RNA Targeting Small Molecules Therapeutics Market Segment Structure?

The rna targeting small molecules therapeutics market covered in this report is segmented –

1) By Offering: mRNA (Messenger Ribonucleic Acid) Translation Modulators, RNA (Ribonucleic Acid) Splicing Modification, Direct RNA (Ribonucleic Acid) Targeting, Other Offerings

2) By Therapeutic Indication: Lung Fibrosis, Cancer, Neurodegenerative Diseases, Autoimmune, Inflammatory, Other Therapeutic Indications

3) By End User: Hospitals, Research Laboratories, Pharmaceutical And Biotechnology Companies, Other End-Users

What Trends Are Influencing The RNA Targeting Small Molecules Therapeutics Market?

Leading companies active in the RNA-targeting small molecule therapeutics market are prioritizing the formation of strategic alliances to improve the discovery and development of novel treatments. These strategic partnerships involve joint efforts between two or more organizations to integrate expertise, share data, and accelerate the creation of innovative RNA-targeting small molecules. For instance, in June 2022, Otsuka Pharmaceutical Co. Ltd., a Japan-based pharmaceutical manufacturing firm, teamed up with xFOREST Therapeutics Co. Ltd., a Japan-based developer of drug discovery platforms. Through this collaboration, xFOREST will provide Otsuka with its Forest technology to advance systemic small-molecule drug discovery research centered on RNA structures. Moreover, in April 2024, Ipsen, a France-based biopharmaceutical company, partnered with Skyhawk Therapeutics, a US-based clinical-stage biotechnology company that offers RNA-targeting small molecule therapeutics. With this alliance, Ipsen sought to develop RNA-targeting small molecule drugs for rare neurological diseases and integrates various data sets to identify and create small molecules capable of modulating RNA.

Who Are The Companies Participating In The RNA Targeting Small Molecules Therapeutics Market?

Major companies operating in the rna targeting small molecules therapeutics market are F Hoffmann La Roche Ltd, Novartis AG, Sanofi SA, AstraZeneca plc, Eli Lilly and Company, Amgen Inc, Bayer AG, Vertex Pharmaceuticals Inc, PTC Therapeutics Inc, Arrakis Therapeutics, Anima Biotech Inc, Skyhawk Therapeutics Inc, Remix Therapeutics, Accent Therapeutics Inc, STORM Therapeutics Ltd, eFFECTOR Therapeutics Inc, EPICS Therapeutics, Expansion Therapeutics Inc, Ribometrix Inc, Redona Therapeutics, Eloxx Pharmaceuticals Inc, 858 Therapeutics

Get The Full RNA Targeting Small Molecules Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

Which Region Represents The Largest Share Of The RNA Targeting Small Molecules Therapeutics Market?

North America was the largest region in the RNA targeting small molecules therapeutics market in 2025. The regions covered in the rna targeting small molecules therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized RNA Targeting Small Molecules Therapeutics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

Browse Through More Reports Similar to the Global RNA Targeting Small Molecules Therapeutics Market 2026, By The Business Research Company

Rna Targeting Small Molecules Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

Rna Targeting Small Molecule Drug Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecule-drug-discovery-global-market-report

Mrna Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/mrna-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The RNA Targeting Small Molecules Therapeutics Market In 2026 And What Value Is Projected For 2030?

The rna targeting small molecules therapeutics market size has experienced significant expansion in recent years. This market is projected to expand from $2.93 billion in 2025 to $3.1 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.8%. Historically, this growth can be linked to factors such as the restricted effectiveness of protein-targeted drugs, increased funding for genomic research, the rising incidence of cancer and genetic disorders, initial breakthroughs in rna-based therapies, and the proliferation of collaborations between academia and industry.

The rna targeting small molecules therapeutics market is projected to experience substantial growth over the next few years. It is forecast to expand to $4.84 billion by 2030, achieving a compound annual growth rate (CAGR) of 11.7%. This anticipated growth throughout the forecast period stems from factors such as advancements in RNA structure prediction, increasing demand for precision therapeutics, a rise in biotech investments focused on small molecules, supportive regulatory environments for novel RNA drugs, and an expanding pipeline of RNA-targeting clinical trials. Significant trends for the forecast period include the broadening of RNA-targeted drug pipelines, a concentrated effort on disease targets previously deemed undruggable, enhanced collaborations between pharmaceutical and biotechnology companies, progress in RNA structural biology and chemistry, and an increase in investment for therapies addressing rare and genetic diseases.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12253&type=smp

What Major Drivers Are Influencing Demand In The RNA Targeting Small Molecules Therapeutics Market?

The increasing number of cancer cases is expected to propel the growth of the RNA-targeting small molecule therapeutics market going forward. Cancer is a category of illnesses that can develop in nearly any organ or tissue in the body when aberrant cells proliferate uncontrollably, cross their usual boundaries, and either spread to other organs or invade neighboring body parts. Cancer is treated with RNA-targeting small molecules created and investigated to target RNA molecules associated with cancer selectively. For instance, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, by 2050, over 35 million new cancer cases are projected, representing a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the increasing number of cancer cases is driving the growth of the RNA-targeting small molecule therapeutics market. The rising incidence of genetic disorders is expected to boost the growth of the RNA-targeting small-molecule therapeutics market going forward. Genetic disorders are conditions caused by abnormalities or mutations in an individual’s genetic material, such as DNA or chromosomes. RNA-targeting small-molecule therapeutics are an exciting emerging field with immense potential for treating genetic disorders. Some genetic disorders involve toxic expansions of repeated RNA sequences. Small molecules can stabilize or destabilize these expansions, potentially mitigating their harmful effects. For instance, in October 2024, according to the Cystic Fibrosis Trust, a UK-based national charity, there were 11,148 people living with cystic fibrosis (CF) in the UK in 2022, increasing to 11,318 in 2023. Therefore, the rising incidence of genetic disorders is driving the growth of the RNA-targeting small-molecule therapeutic market.

What Are The Key Segments Of The RNA Targeting Small Molecules Therapeutics Market?

The rna targeting small molecules therapeutics market covered in this report is segmented –

1) By Offering: mRNA (Messenger Ribonucleic Acid) Translation Modulators, RNA (Ribonucleic Acid) Splicing Modification, Direct RNA (Ribonucleic Acid) Targeting, Other Offerings

2) By Therapeutic Indication: Lung Fibrosis, Cancer, Neurodegenerative Diseases, Autoimmune, Inflammatory, Other Therapeutic Indications

3) By End User: Hospitals, Research Laboratories, Pharmaceutical And Biotechnology Companies, Other End-Users

What Key Trends Are Influencing The Development Of The RNA Targeting Small Molecules Therapeutics Market?

Leading entities within the RNA-targeting small molecule therapeutics market are prioritizing the establishment of strategic alliances to boost the innovation and advancement of new treatments. These collaborations typically involve multiple organizations uniting their specialized knowledge, sharing crucial data, and speeding up the generation of cutting-edge RNA-targeting small molecules. For example, June 2022 saw Otsuka Pharmaceutical Co. Ltd., a pharmaceutical manufacturing firm based in Japan, enter into a collaboration with xFOREST Therapeutics Co. Ltd., a Japan-based developer of drug discovery platforms. Through this alliance, xFOREST committed to providing Otsuka with its proprietary Forest technology to further systemic small-molecule drug discovery research specifically targeting RNA structures. Additionally, in April 2024, Ipsen, a biopharmaceutical company from France, joined forces with Skyhawk Therapeutics, a US-based clinical-stage biotechnology firm specializing in RNA-targeting small molecule therapeutics. This cooperative effort allowed Ipsen to focus on creating RNA-targeting small molecule drugs for rare neurological conditions, by integrating diverse data sets to pinpoint and formulate small molecules capable of modulating RNA.

Who Are The Leading Companies Operating In The RNA Targeting Small Molecules Therapeutics Market?

Major companies operating in the rna targeting small molecules therapeutics market are F Hoffmann La Roche Ltd, Novartis AG, Sanofi SA, AstraZeneca plc, Eli Lilly and Company, Amgen Inc, Bayer AG, Vertex Pharmaceuticals Inc, PTC Therapeutics Inc, Arrakis Therapeutics, Anima Biotech Inc, Skyhawk Therapeutics Inc, Remix Therapeutics, Accent Therapeutics Inc, STORM Therapeutics Ltd, eFFECTOR Therapeutics Inc, EPICS Therapeutics, Expansion Therapeutics Inc, Ribometrix Inc, Redona Therapeutics, Eloxx Pharmaceuticals Inc, 858 Therapeutics

Read the full rna targeting small molecules therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The RNA Targeting Small Molecules Therapeutics Market?

North America was the largest region in the RNA targeting small molecules therapeutics market in 2025. The regions covered in the rna targeting small molecules therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored RNA Targeting Small Molecules Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12253&type=smp

Browse Through More Reports Similar to the Global RNA Targeting Small Molecules Therapeutics Market 2026, By The Business Research Company

Rna Targeting Small Molecules Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

Rna Targeting Small Molecule Drug Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecule-drug-discovery-global-market-report

Mrna Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/mrna-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the rna targeting small molecules therapeutics market from 2026–2035 with trusted insights from The Business Research Company

What growth pattern is forecast for the RNA Targeting Small Molecules Therapeutics Market size between 2026 and 2035?

The rna targeting small molecules therapeutics market has shown robust expansion in recent years. This market is projected to grow from $2.93 billion in 2025 to $3.1 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.8%. Historically, this growth can be attributed to factors such as the limited efficacy of protein-targeted drugs, increased funding for genomic research, the rising prevalence of cancer and genetic disorders, the early successes of rna-based therapies, and the expansion of academic-industry collaborations.

The rna targeting small molecules therapeutics market is projected to experience substantial expansion in the coming years. Its valuation is anticipated to reach $4.84 billion by 2030, exhibiting an impressive compound annual growth rate (CAGR) of 11.7%. This growth over the forecast period stems from several key factors, such as advancements in rna structure prediction, a heightened demand for precision therapeutics, increased biotech investments in small molecules, strong regulatory backing for novel rna drugs, and an expanding pipeline of rna-targeting clinical trials. Significant developments anticipated during this timeframe encompass the broadening of rna-targeted drug pipelines, an intensifying focus on disease targets previously considered undruggable, enhanced cooperation between pharmaceutical and biotechnology companies, breakthroughs in rna structural biology and chemistry, and a surge in investment towards therapies for rare and genetic diseases.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12253&type=smp

Which Drivers Are Impacting Market Performance In The RNA Targeting Small Molecules Therapeutics Market?

A rising prevalence of cancer is anticipated to fuel the expansion of the RNA-targeting small molecule therapeutics market in the future. Cancer refers to a group of diseases that can arise in almost any bodily organ or tissue, characterized by the unchecked proliferation of abnormal cells that surpass their normal limits, potentially spreading to other organs or invading adjacent areas. RNA-targeting small molecules are developed and studied for cancer treatment, designed to selectively target RNA molecules linked to the disease. For instance, the World Health Organization, a Switzerland-based intergovernmental organization, reported in February 2024 that by 2050, new cancer cases are expected to exceed 35 million, marking a 77% rise from the approximately 20 million cases estimated in 2022. Consequently, the growing incidence of cancer cases is propelling the growth of the RNA-targeting small molecule therapeutics market.

What Segment Types Are Examined In The RNA Targeting Small Molecules Therapeutics Market?

The rna targeting small molecules therapeutics market covered in this report is segmented –

1) By Offering: mRNA (Messenger Ribonucleic Acid) Translation Modulators, RNA (Ribonucleic Acid) Splicing Modification, Direct RNA (Ribonucleic Acid) Targeting, Other Offerings

2) By Therapeutic Indication: Lung Fibrosis, Cancer, Neurodegenerative Diseases, Autoimmune, Inflammatory, Other Therapeutic Indications

3) By End User: Hospitals, Research Laboratories, Pharmaceutical And Biotechnology Companies, Other End-Users

What Trends Are Projected To Support The Growth Of The RNA Targeting Small Molecules Therapeutics Market?

Leading firms within the RNA-targeting small molecule therapeutics market are concentrating on forging strategic alliances to boost the innovation and advancement of new treatments. Such alliances entail cooperation among multiple entities, pooling specialized knowledge, exchanging information, and expediting the production of groundbreaking RNA-targeting small molecules. A notable instance occurred in June 2022 when Otsuka Pharmaceutical Co. Ltd., a Japan-based pharmaceutical manufacturer, entered into a collaboration with xFOREST Therapeutics Co. Ltd., a Japan-based firm specializing in drug discovery platforms. Through this arrangement, xFOREST will provide Otsuka with its Forest technology to further systemic small-molecule drug discovery efforts centered on RNA structures. Additionally, in April 2024, Ipsen, a France-based biopharmaceutical company, formed a partnership with Skyhawk Therapeutics, a US-based clinical-stage biotechnology company that offers RNA-targeting small molecule therapeutics. This joint effort enabled Ipsen to pursue the development of RNA-targeting small molecule drugs for uncommon neurological conditions, incorporating diverse data sets to pinpoint and create small molecules capable of modulating RNA.

Who Are The Top-Performing Companies In The RNA Targeting Small Molecules Therapeutics Market In Recent Years?

Major companies operating in the rna targeting small molecules therapeutics market are F Hoffmann La Roche Ltd, Novartis AG, Sanofi SA, AstraZeneca plc, Eli Lilly and Company, Amgen Inc, Bayer AG, Vertex Pharmaceuticals Inc, PTC Therapeutics Inc, Arrakis Therapeutics, Anima Biotech Inc, Skyhawk Therapeutics Inc, Remix Therapeutics, Accent Therapeutics Inc, STORM Therapeutics Ltd, eFFECTOR Therapeutics Inc, EPICS Therapeutics, Expansion Therapeutics Inc, Ribometrix Inc, Redona Therapeutics, Eloxx Pharmaceuticals Inc, 858 Therapeutics

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

Which Region Currently Holds The Largest Share Of The RNA Targeting Small Molecules Therapeutics Market?

North America was the largest region in the RNA targeting small molecules therapeutics market in 2025. The regions covered in the rna targeting small molecules therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized RNA Targeting Small Molecules Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12253&type=smp

Browse Through More Reports Similar to the Global RNA Targeting Small Molecules Therapeutics Market 2026, By The Business Research Company

Rna Targeting Small Molecules Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

Rna Targeting Small Molecule Drug Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecule-drug-discovery-global-market-report

Mrna Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/mrna-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the rna targeting small molecules therapeutics market from 2025–2034 with trusted insights from The Business Research Company

What Are The Market Size Estimates For The RNA Targeting Small Molecules Therapeutics Market Now And By 2029?

The market size for RNA targeting small molecules therapeutics has experienced substantial expansion in recent years. This sector is forecast to increase from $6.1 billion in 2024 to $7.83 billion in 2025, reflecting a compound annual growth rate (CAGR) of 28.3%. The historical surge can be attributed to drug discovery and development, the rising prevalence of RNA-related diseases, government and private funding, pharmaceutical industry interest, and RNA therapeutics success stories.

The RNA targeting small molecules therapeutics market is projected to experience substantial growth in the coming years. It is anticipated to expand to $21.95 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 29.4%. The factors contributing to this growth during the forecast period include the emergence of precision medicine and personalized therapies, an increase in RNA biomarker identification, an expanding RNA target spectrum, rising funding and investments, and its application in rare diseases. Key trends expected in the forecast period encompass advancements in screening technologies, the dominance of antisense oligonucleotides, the development of small molecule RNA binders, the use of RNA therapeutics in neurological disorders, and gene editing with CRISPR-Cas9.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12253&type=smp

Which Long-Term Drivers Are Expected To Sustain The RNA Targeting Small Molecules Therapeutics Market?

The RNA-targeting small molecule therapeutics market is projected to expand due to the rising incidence of cancer cases in the future. Cancer refers to a group of diseases that can emerge in almost any bodily organ or tissue, characterized by the uncontrolled proliferation of abnormal cells that surpass their normal limits, potentially spreading to other organs or infiltrating adjacent areas. Treatment for cancer involves RNA-targeting small molecules, specifically designed and studied to selectively target RNA molecules linked to the disease. An illustrative example comes from January 2022, where the American Cancer Society, a health organization based in the US, reported research anticipating 609,360 cancer deaths and 1.9 million new cancer cases in the US for 2022. This translates to approximately 1,670 daily fatalities. Consequently, the growing count of cancer cases is stimulating the expansion of the RNA-targeting small molecule therapeutics market.

How Is The RNA Targeting Small Molecules Therapeutics Market Classified By Different Segments?

The rna targeting small molecules therapeutics market covered in this report is segmented –

1) By Offering: mRNA (Messenger Ribonucleic Acid) Translation Modulators, RNA (Ribonucleic Acid) Splicing Modification, Direct RNA (Ribonucleic Acid) Targeting, Other Offerings

2) By Therapeutic Indication: Lung Fibrosis, Cancer, Neurodegenerative Diseases, Autoimmune, Inflammatory, Other Therapeutic Indications

3) By Application: Drug Discovery, Oncology Research, Disease Identification

4) By End User: Hospitals, Research Laboratories, Pharmaceutical And Biotechnology Companies, Other End-Users

Subsegments:

1) By mRNA (Messenger Ribonucleic Acid) Translation Modulators: Small Molecule Inhibitors, Enhancers Of Translation

2) By RNA (Ribonucleic Acid) Splicing Modification: Splicing Modulators, Antisense Oligonucleotides

3) By Direct RNA (Ribonucleic Acid) Targeting: RNA-Binding Small Molecules, RNA Aptamers

4) By Other Offerings: RNA Interference (RNAi) Therapeutics, Small Molecule Activators Of RNA Stability

What Current And Upcoming Trends Are Shaping The RNA Targeting Small Molecules Therapeutics Market?

Strategic partnerships are becoming a prominent trend in the RNA-targeting small molecule therapeutics market. Leading companies in the RNA-targeting small molecule therapeutics market are engaging in collaborations to forge new relationships where multiple organizations can develop innovative products. For example, in June 2022, Otsuka Pharmaceutical Co. Ltd., a Japan-based pharmaceutical manufacturing company, collaborated with xFOREST Therapeutics Co. Ltd., a Japan-based developer of drug discovery platforms. Through this partnership, xFOREST will furnish Otsuka with its Forest technology to advance systemic small-molecule drug discovery research concentrating on RNA structures. Furthermore, in April 2024, Ipsen, a France-based biopharmaceutical company, allied with Skyhawk Therapeutics, a US-based clinical-stage biotechnology company that offers RNA-targeting small molecule therapeutics. This collaboration allowed Ipsen to focus on creating RNA-targeting small molecule drugs for rare neurological diseases and to integrate various data sets to pinpoint and develop small molecules capable of modulating RNA.

Who Are The Primary Market Leaders In The RNA Targeting Small Molecules Therapeutics Market?

Major companies operating in the RNA targeting small molecules therapeutics market include F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Amgen Inc., Janssen Pharmaceuticals, Vertex Pharmaceuticals, Servier laboratories, Genentech Inc., PTC Therapeutics Inc., Arrakis Therapeutics, Anima Biotech Inc., Skyhawk Therapeutics Inc., Remix Therapeutics, Abivax SA, 858 Therapeutics, Eloxx Pharmaceuticals Inc., STORM Therapeutics Ltd., Accent Therapeutics Inc., eFFECTOR Therapeutics Inc., EPICS Therapeutics, Expansion Therapeutics Inc., Inspirna Inc., MiNA Therapeutics Ltd., Ribometrix Inc., AC Immune SA, Redona Therapeutics

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

Which Regional Markets Are Emerging As Key Centers For The RNA Targeting Small Molecules Therapeutics Market?

North America was the largest region in the RNA targeting small molecules therapeutics market in 2024. The regions covered in the RNA targeting small molecules therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=12253&type=smp

Browse Through More Reports Similar to the Global RNA Targeting Small Molecules Therapeutics Market 2025, By The Business Research Company

Cranes Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cranes-global-market-report

Overhead Cranes Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/overhead-cranes-global-market-report

Rubber Tired Gantry Crane Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/rubber-tired-gantry-crane-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Market Value Is The RNA Targeting Small Molecules Therapeutics Industry Expected To Reach By 2029, Starting From 2025 Levels?

The RNA targeting small molecules therapeutics market size has experienced significant expansion in recent years. Its valuation is projected to rise from $6.1 billion in 2024 to $7.83 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 28.3%. This historical growth can be ascribed to elements such as drug discovery and development efforts, the increasing prevalence of RNA-related diseases, governmental and private financial backing, strong interest from the pharmaceutical industry, and successful applications of RNA therapeutics.

The market for RNA targeting small molecules therapeutics is projected to experience rapid expansion in the coming years. This market is anticipated to reach a valuation of $21.95 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 29.4%. Factors driving this growth during the forecast period include precision medicine and personalized therapies, the rise in RNA biomarker identification, an expanding RNA target spectrum, increasing funding and investments, and its application in rare diseases. Key trends identified for the forecast period encompass advancements in screening technologies, the dominance of antisense oligonucleotides, the development of small molecule RNA binders, the application of RNA therapeutics in neurological disorders, and gene editing with crispr-cas9.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12253&type=smp

What Are The Main Drivers Boosting The RNA Targeting Small Molecules Therapeutics Industry’s Expansion?

The rising number of cancer cases is anticipated to drive the expansion of the RNA-targeting small molecule therapeutics market moving forward. Cancer is a class of illnesses that can develop in nearly any bodily organ or tissue when abnormal cells reproduce uncontrollably, cross their usual boundaries, and either spread to other organs or invade neighboring body parts. RNA-targeting small molecules, specifically designed and investigated to selectively target RNA molecules associated with cancer, are used to treat the disease. For instance, in January 2022, research published by the American Cancer Society, a US-based health organization, projected 609,360 cancer deaths and 1.9 million new cancer cases in the US for 2022. This amounts to approximately 1,670 fatalities each day. Therefore, the increasing incidence of cancer cases is fueling the growth of the RNA-targeting small molecule therapeutics market.

What Are The Primary Types Of Segments Analyzed In The RNA Targeting Small Molecules Therapeutics Market?

The rna targeting small molecules therapeutics market covered in this report is segmented –

1) By Offering: mRNA (Messenger Ribonucleic Acid) Translation Modulators, RNA (Ribonucleic Acid) Splicing Modification, Direct RNA (Ribonucleic Acid) Targeting, Other Offerings

2) By Therapeutic Indication: Lung Fibrosis, Cancer, Neurodegenerative Diseases, Autoimmune, Inflammatory, Other Therapeutic Indications

3) By Application: Drug Discovery, Oncology Research, Disease Identification

4) By End User: Hospitals, Research Laboratories, Pharmaceutical And Biotechnology Companies, Other End-Users

Subsegments:

1) By mRNA (Messenger Ribonucleic Acid) Translation Modulators: Small Molecule Inhibitors, Enhancers Of Translation

2) By RNA (Ribonucleic Acid) Splicing Modification: Splicing Modulators, Antisense Oligonucleotides

3) By Direct RNA (Ribonucleic Acid) Targeting: RNA-Binding Small Molecules, RNA Aptamers

4) By Other Offerings: RNA Interference (RNAi) Therapeutics, Small Molecule Activators Of RNA Stability

What Trends Are Redefining The RNA Targeting Small Molecules Therapeutics Market Dynamics?

A notable and increasingly prevalent development within the RNA-targeting small molecule therapeutics market is the rise of strategic partnerships. Leading firms in the RNA-targeting small molecule therapeutics market are forming alliances to establish novel relationships, enabling multiple entities to co-create innovative products. An example of this is the collaboration in June 2022 between Otsuka Pharmaceutical Co. Ltd., a pharmaceutical manufacturer based in Japan, and xFOREST Therapeutics Co. Ltd., a Japan-based company specializing in drug discovery platform development. Through this collaboration, xFOREST will provide Otsuka with its proprietary Forest technology to further systemic small-molecule drug discovery research, specifically targeting RNA structures. Additionally, in April 2024, Ipsen, a biopharmaceutical firm from France, entered into a partnership with Skyhawk Therapeutics, a US-based clinical-stage biotechnology company known for its RNA-targeting small molecule therapeutics. This collaboration aimed to enable Ipsen to develop RNA-targeting small molecule drugs for rare neurological diseases, integrating diverse data sets to pinpoint and create small molecules capable of modulating RNA.

Which Industry Leaders Are Driving Innovation Across The RNA Targeting Small Molecules Therapeutics Market?

Major companies operating in the RNA targeting small molecules therapeutics market include F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Amgen Inc., Janssen Pharmaceuticals, Vertex Pharmaceuticals, Servier laboratories, Genentech Inc., PTC Therapeutics Inc., Arrakis Therapeutics, Anima Biotech Inc., Skyhawk Therapeutics Inc., Remix Therapeutics, Abivax SA, 858 Therapeutics, Eloxx Pharmaceuticals Inc., STORM Therapeutics Ltd., Accent Therapeutics Inc., eFFECTOR Therapeutics Inc., EPICS Therapeutics, Expansion Therapeutics Inc., Inspirna Inc., MiNA Therapeutics Ltd., Ribometrix Inc., AC Immune SA, Redona Therapeutics

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

What Regional Growth Trends Are Shaping The RNA Targeting Small Molecules Therapeutics Market Outlook?

North America was the largest region in the RNA targeting small molecules therapeutics market in 2024. The regions covered in the RNA targeting small molecules therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The RNA Targeting Small Molecules Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=12253&type=smp

Browse Through More Reports Similar to the Global RNA Targeting Small Molecules Therapeutics Market 2025, By The Business Research Company

Cranes Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cranes-global-market-report

Overhead Cranes Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/overhead-cranes-global-market-report

Rubber Tired Gantry Crane Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/rubber-tired-gantry-crane-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model